Diagnosis of Endocrine Disease: Evaluation of bone fragility in endocrine disorders

Cristina Eller-Vainicher, Alberto Falchetti, Luigi Gennari, Elisa Cairoli, Francesco Bertoldo, Fabio Vescini, Alfredo Scillitani, Iacopo Chiodini

Research output: Contribution to journalReview article

Abstract

An underlying disease affecting bone health is present in up to 40 and 60% of osteoporotic postmenopausal women and men respectively. Among the disorders leading to a secondary form of osteoporosis, the endocrine diseases are highly represented. A frequent finding in patients affected with an endocrine-related forms of bone disease is that the skeletal fragility is partially independent of the bone density, since the fracture risk in these patients is related more to a reduction of bone quality than to a decrease of bone mass. As a consequence, bone mineral density evaluation by dual-X-ray absorptiometry may be inadequate for establishing the risk of fracture in the setting of the endocrinerelated forms of osteoporosis. In the recent years, several attempts to non-invasively estimating bone quality have been done. Nowadays, some new tools are available in the clinic al practice for optimising the fracture risk estimation in patients with endocrine disorders. The aim of this review is to summarise the evidence regarding the role of the different imaging tools for evaluating bone density and bone qua lity in the most frequent forms of endocrine-related osteoporosis, such as obesity, diabetes, acromegaly, thyrotoxicosis, primary hyperparathyroidism, hypercortisolism and hypogonadism. For each of these disorders, data regarding both the current available tools and the future possible new techniques for assessing bone fragility in patient s with endocrine diseases are reported.

Original languageEnglish
Pages (from-to)R213-R232
JournalEuropean Journal of Endocrinology
Volume180
Issue number6
DOIs
Publication statusPublished - Jun 1 2019

Fingerprint

Endocrine Bone Diseases
Bone and Bones
Bone Density
Osteoporosis
Endocrine System Diseases
Bone Diseases
Acromegaly
Thyrotoxicosis
Hypogonadism
Primary Hyperparathyroidism
Cushing Syndrome
Photon Absorptiometry
Obesity
Health

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Diagnosis of Endocrine Disease : Evaluation of bone fragility in endocrine disorders. / Eller-Vainicher, Cristina; Falchetti, Alberto; Gennari, Luigi; Cairoli, Elisa; Bertoldo, Francesco; Vescini, Fabio; Scillitani, Alfredo; Chiodini, Iacopo.

In: European Journal of Endocrinology, Vol. 180, No. 6, 01.06.2019, p. R213-R232.

Research output: Contribution to journalReview article

@article{103a3cd915f346d98f7aa8abc763d95c,
title = "Diagnosis of Endocrine Disease: Evaluation of bone fragility in endocrine disorders",
abstract = "An underlying disease affecting bone health is present in up to 40 and 60{\%} of osteoporotic postmenopausal women and men respectively. Among the disorders leading to a secondary form of osteoporosis, the endocrine diseases are highly represented. A frequent finding in patients affected with an endocrine-related forms of bone disease is that the skeletal fragility is partially independent of the bone density, since the fracture risk in these patients is related more to a reduction of bone quality than to a decrease of bone mass. As a consequence, bone mineral density evaluation by dual-X-ray absorptiometry may be inadequate for establishing the risk of fracture in the setting of the endocrinerelated forms of osteoporosis. In the recent years, several attempts to non-invasively estimating bone quality have been done. Nowadays, some new tools are available in the clinic al practice for optimising the fracture risk estimation in patients with endocrine disorders. The aim of this review is to summarise the evidence regarding the role of the different imaging tools for evaluating bone density and bone qua lity in the most frequent forms of endocrine-related osteoporosis, such as obesity, diabetes, acromegaly, thyrotoxicosis, primary hyperparathyroidism, hypercortisolism and hypogonadism. For each of these disorders, data regarding both the current available tools and the future possible new techniques for assessing bone fragility in patient s with endocrine diseases are reported.",
author = "Cristina Eller-Vainicher and Alberto Falchetti and Luigi Gennari and Elisa Cairoli and Francesco Bertoldo and Fabio Vescini and Alfredo Scillitani and Iacopo Chiodini",
year = "2019",
month = "6",
day = "1",
doi = "10.1530/EJE-18-0991",
language = "English",
volume = "180",
pages = "R213--R232",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "6",

}

TY - JOUR

T1 - Diagnosis of Endocrine Disease

T2 - Evaluation of bone fragility in endocrine disorders

AU - Eller-Vainicher, Cristina

AU - Falchetti, Alberto

AU - Gennari, Luigi

AU - Cairoli, Elisa

AU - Bertoldo, Francesco

AU - Vescini, Fabio

AU - Scillitani, Alfredo

AU - Chiodini, Iacopo

PY - 2019/6/1

Y1 - 2019/6/1

N2 - An underlying disease affecting bone health is present in up to 40 and 60% of osteoporotic postmenopausal women and men respectively. Among the disorders leading to a secondary form of osteoporosis, the endocrine diseases are highly represented. A frequent finding in patients affected with an endocrine-related forms of bone disease is that the skeletal fragility is partially independent of the bone density, since the fracture risk in these patients is related more to a reduction of bone quality than to a decrease of bone mass. As a consequence, bone mineral density evaluation by dual-X-ray absorptiometry may be inadequate for establishing the risk of fracture in the setting of the endocrinerelated forms of osteoporosis. In the recent years, several attempts to non-invasively estimating bone quality have been done. Nowadays, some new tools are available in the clinic al practice for optimising the fracture risk estimation in patients with endocrine disorders. The aim of this review is to summarise the evidence regarding the role of the different imaging tools for evaluating bone density and bone qua lity in the most frequent forms of endocrine-related osteoporosis, such as obesity, diabetes, acromegaly, thyrotoxicosis, primary hyperparathyroidism, hypercortisolism and hypogonadism. For each of these disorders, data regarding both the current available tools and the future possible new techniques for assessing bone fragility in patient s with endocrine diseases are reported.

AB - An underlying disease affecting bone health is present in up to 40 and 60% of osteoporotic postmenopausal women and men respectively. Among the disorders leading to a secondary form of osteoporosis, the endocrine diseases are highly represented. A frequent finding in patients affected with an endocrine-related forms of bone disease is that the skeletal fragility is partially independent of the bone density, since the fracture risk in these patients is related more to a reduction of bone quality than to a decrease of bone mass. As a consequence, bone mineral density evaluation by dual-X-ray absorptiometry may be inadequate for establishing the risk of fracture in the setting of the endocrinerelated forms of osteoporosis. In the recent years, several attempts to non-invasively estimating bone quality have been done. Nowadays, some new tools are available in the clinic al practice for optimising the fracture risk estimation in patients with endocrine disorders. The aim of this review is to summarise the evidence regarding the role of the different imaging tools for evaluating bone density and bone qua lity in the most frequent forms of endocrine-related osteoporosis, such as obesity, diabetes, acromegaly, thyrotoxicosis, primary hyperparathyroidism, hypercortisolism and hypogonadism. For each of these disorders, data regarding both the current available tools and the future possible new techniques for assessing bone fragility in patient s with endocrine diseases are reported.

UR - http://www.scopus.com/inward/record.url?scp=85066292396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066292396&partnerID=8YFLogxK

U2 - 10.1530/EJE-18-0991

DO - 10.1530/EJE-18-0991

M3 - Review article

C2 - 31042675

AN - SCOPUS:85066292396

VL - 180

SP - R213-R232

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 6

ER -